Dr. Coy D. Heldermon, MD

Dr. Heldermon practices at UF Health Shands Hospital in Gainesville, Florida, part of UF Health.

Dr. Heldermon's NPI, 1467474502, was assigned on July 25, 2006. Dr. Heldermon graduated from OU College of Medicine in 2001. Dr. Heldermon holds Florida license ME104836.

Dr. Heldermon's primary practice is UF Health Shands Hospital, at 1600 SW Archer Rd, Gainesville, FL 32610 in Alachua County. The practice phone is (352) 265-8000.

Dr. Heldermon's primary practice is UF Health Shands Hospital in Gainesville, Florida, part of UF Health. The medical group on file is UF Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Heldermon practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Heldermon's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Heldermon is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Heldermon's licenses on file in 2 states: Florida and Missouri.

Dmand AI lists breast cancer, lung cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Heldermon treats.

CMS data shows 529 Medicare services from Dr. Heldermon across 9 procedure codes in 2024, for 239 Medicare patients. Medicare paid $37,811 for them.

CMS counts 239 Medicare patients who saw Dr. Heldermon in 2024. The largest group is 65 to 74, with 117 patients. 75% of them have cancer, and 75% have high blood pressure. 16% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Heldermon's median patient age at 72, with 84% women.

In 2024, Dr. Heldermon wrote 820 Medicare Part D claims for 199 patients. 88% of them were for generic drugs. CMS names the drug for 732 of them, across 16 drugs with 11 or more claims each, at $1,179,400 in total drug cost. In 2023, CMS named 552 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 48 out of 100 for Dr. Heldermon for performance year 2024, reported through an alternative payment model (APM). Dr. Heldermon accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Heldermon as offering telehealth.

Dmand AI links 58 papers to Dr. Heldermon, published from 2000 to 2025. 2015 was the busiest year, with 5. The most frequent topics are Breast Neoplasms, Membrane Proteins and Mucopolysaccharidosis III. Dr. Heldermon has published most often in Gene Ther. Dr. Heldermon's most frequent co-authors are Paul G. Okunieff, MD, Julie Ann Bradley, MD and Mark Louis Brantly, MD.

Dmand AI links Dr. Heldermon to 5 clinical trials, 3 of them phase 1/2 studies. Conditions studied include Fabry Disease, Breast Neoplasms and Mucopolysaccharidosis I. Sangamo Therapeutics sponsors the most, 2.

CMS Open Payments shows 49 general payments to Dr. Heldermon from 11 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 55% of the total. Sanofi and Genzyme US Companies paid the most, $36,223.

Dr. Heldermon graduated from OU College of Medicine in 2001. Dr. Heldermon is a member of ASCO.

Dr. Heldermon is in network with 17 carriers, including Aetna, Excellus BlueCross BlueShield and Elevance. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.